Second Reported Human Infection With Rare Nocardia Niigatensis, Patient Dies

Two and a half liters of pus drained from a 36-year-old man’s leg turned out to be only the second recorded human infection with Nocardia niigatensis, a bacterium first identified in Japan in 2004, Cureus reported in a case study published this week.

The patient, immunosuppressed for myasthenia gravis, survived the infection but not the two cardiac arrests that preceded it.

The report matters for a reason that sits squarely at the intersection of clinical medicine and instrumentation: this diagnosis was made possible by mass spectrometry and gene sequencing, not by anything visible on a microscope slide. And the diagnostic chain almost broke at every link.

A Skin Rash That Fooled Everyone

The patient arrived in February 2025 with fever, bilateral leg swelling, and a day-old loss of consciousness. He had been on prednisolone 60 mg daily and pyridostigmine for myasthenia gravis, and had already failed a course of oral Augmentin prescribed elsewhere. The scattered lesions across his limbs and neck looked, per the Cureus report, like tinea — ringworm, essentially — with peripheral hyperpigmentation and central fading.

That mimicry is the core problem. Cutaneous nocardiosis can resemble fungal or mycobacterial infection, delaying recognition, and skin findings do not reliably indicate systemic involvement. In the emergency department he arrested twice, was resuscitated, intubated, and put on three vasopressors before surgeons evacuated abscesses running from his right thigh to the ankle.

His labs read like a sepsis textbook: a white cell count of 38.33 × 10³/µL against a reference ceiling of 11.0, a C-reactive protein of 365 mg/L where normal is under 5, and an INR of 1.59. Blood cultures, sputum, and urine all came back negative or irrelevant. The pathogen was hiding in the tissue.

Test Result Reference
White blood cells 38.33 × 10³/µL 4.0–11.0 × 10³/µL
Absolute neutrophils 36 × 10³/µL 2.0–7.5 × 10³/µL
C-reactive protein 365 mg/L <5 mg/L
ALT 318.31 U/L 0–41 U/L
INR 1.59 0.8–1.1

How the Machines Got It Right

Microscopy showed branching filamentous Gram-positive bacilli — a signature that narrows things to Nocardia and a few lookalikes but stops well short of species. After 48 hours on blood and chocolate agar, the cultures produced dry, chalky colonies with white and orange pigmentation.

Then the instrumentation took over. A Bruker MALDI Biotyper running MBT Compass 4.1.100 flagged N. niigatensis by shooting intact bacterial proteins through a time-of-flight mass spectrometer and matching the resulting spectral fingerprint against a reference database.

A reference laboratory then confirmed the call the old-fashioned way: PCR amplification of the 16S rRNA gene using the universal 27F and 519R primers, producing a 464-base-pair sequence with 100% homology to N. niigatensis and 99% query coverage against reference accession NR_117402.

The near-misses are the interesting part. The closest related species scored 97.84% (N. acididurans) and 97.41% (N. tengchongensis and N. acidivorans). In a 464-base read, that few-percent gap is everything — and it is precisely the zone where MALDI-TOF databases, which are only as good as the reference spectra they contain, tend to misidentify uncommon organisms.

Cureus notes that rare species may still be misidentified even with both methods in play, which is why the report leans on dual confirmation.

Why This Species Is a Statistical Ghost

More than 30 Nocardia species infect humans, but three — N. cyriacigeorgica, N. farcinica, and N. brasiliensis — account for most of it. N. niigatensis was named for Niigata, Japan, where the strain was first isolated, and identified in human clinical specimens there in 2004. The only previously reported human infection was a cutaneous case in a renal transplant recipient. A review of Nocardia species spanning 2006 to 2021 identified no additional cases.

The myasthenia gravis angle narrows the population at risk further. Fewer than 30 nocardiosis cases have been described in MG patients, nearly all on corticosteroids or other immunosuppressants. The report points to thymic-related T-cell dysfunction, chronic steroid exposure, and aspiration risk as the suspected susceptibility factors — and the aspiration link held here, with chest imaging showing bilateral opacities consistent with aspiration pneumonia rather than pulmonary nocardiosis.

The Treatment Math, and What It Cost

Once the organism was identified, vancomycin and clindamycin were dropped and intravenous trimethoprim-sulfamethoxazole at 15 mg/kg/day (TMP component) went in, with meropenem continued for a month. The skin lesions improved steadily through six months of therapy — one month IV, then five months of oral TMP-SMX monotherapy at 5 mg/kg/day — before the patient returned to his home country.

The infection resolved. The brain did not. Diffuse edema and loss of gray-white matter differentiation on CT, mirrored on MRI, confirmed hypoxic-ischemic injury from the cardiac arrests. He was discharged bedridden at a Glasgow Coma Scale of 8/15 (E4V1M3), enterally fed via a nasogastric tube, with tracheostomy care and minimal ventilatory support. No further follow-up was available, as the patient returned to his home country after six months.

The Open Question

The authors are explicit about why they published at all: with two human cases ever recorded, there is no data on optimal management, clinical spectrum, or reliable identification of this organism. Every additional case is the dataset.

Whether N. niigatensis is genuinely rare or simply under-identified — filed away as “Nocardia species” by labs without MALDI-TOF reference spectra or sequencing access — is the question the report leaves unanswered, and one that only more cases, and more labs with sequencing on hand, can settle.

Photo of author

Technology Desk

Technology Desk at Archyde.

18 Hurt in Multi-Vehicle Crash on Columbia Highway 63

SAFE Food Pantry Serves Allergen-Free Groceries